Solumed Sp. z o.o. sp.k.

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Crohn's disease5 trials
• Migraine5 trials
• Psoriasis4 trials
• Ulcerative colitis3 trials
• Hidradenitis suppurativa2 trials
• Rheumatoid arthritis2 trials
• Atopic dermatitis (eczema)1 trial
• Atrial fibrillation1 trial
• Coeliac disease1 trial
• Osteoporosis1 trial
• Psoriatic arthritis1 trial
• Stroke1 trial

Phase

• Phase 315 trials
• Phase 26 trials
• Phase 42 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Completed14 trials
• Active, not recruiting8 trials
• Recruiting3 trials

Lead sponsor

• Hoffmann-La Roche3 trials
• AbbVie2 trials
• Merz Therapeutics GmbH2 trials
• Alimentiv Inc.1 trial
• Arena Pharmaceuticals Inc.1 trial
• and 16 more

Running trials

• Recruiting

  An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

  NCT07665723· Phase 1· Hoffmann-La Roche· Source

• Active, not recruiting

  A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

  NCT07018713· Phase 3· Merz Therapeutics GmbH· Source

• Active, not recruiting

  A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

  NCT07018700· Phase 3· Merz Therapeutics GmbH· Source

• Active, not recruiting

  Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

  NCT06993610· Phase 2· Zura Bio Inc· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  NCT06602479· Phase 2· AbbVie· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

  NCT06557772· Phase 2· Sanofi· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· AstraZeneca· Source

• Recruiting

  VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

  NCT06257706· Phase 4· Alimentiv Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis

  2024-510826-16-00· Phase 3· Mabxience Research S.L.· Source

• Active, not recruiting

  A trial to learn how safe AZD7798 is and how well it works in adults with ileal Crohn’s disease who have an ileostomy

  2024-514407-33-00· Phase 2· AstraZeneca AB· Source

• Completed

  A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis

  2024-512417-41-00· Phase 3· Xentria Inc.· Source

• Completed

  A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis

  2023-506664-14-00· Phase 3· Dr Reddy's Laboratories Limited· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Completed

  Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis

  NCT05370885· Phase 2· Vedanta Biosciences Inc.· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

  NCT04306315· Phase 4· LEO Pharma· Source

• Completed

  A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

  2024-513569-38-00· Phase 2/3· Arena Pharmaceuticals Inc.· Source

• Completed

  Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

  NCT04921384· Phase 3· H. Lundbeck A/S· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· AbbVie· Source

• Completed

  Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

  NCT04314544· Phase 3· Sun Pharmaceutical Industries Limited· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Bristol-Myers Squibb· Source